Tricuspid Transcatheter Edge-to-Edge Repair Explored in Severe Tricuspid Regurgitation
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 6, 2024 -- For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid transcatheter edge-to-edge repair (T-TEER) yields significant improvements in primary end points, according to a study published online Oct. 27 in the Journal of the American College of Cardiology to coincide with the annual Transcatheter Cardiovascular Therapeutics conference, held from Oct. 27 to 30 in Washington, D.C.
Gilbert H.L. Tang, M.D., from the Mount Sinai Medical System in New York City, and colleagues examined outcomes from the randomized cohort of the TRILUMINATE Pivotal trial to assess the impact of TR reduction with T-TEER with the TriClip device. A total of 572 individuals with symptomatic, severe TR were randomly assigned (350 in the primary cohort; 222 in subsequent enrollment).
The researchers found that the primary end point (hierarchical composite of all-cause mortality or tricuspid valve surgery, heart failure hospitalizations [HFH], and quality-of-life improvement measured by the Kansas City Cardiomyopathy Questionnaire [KCCQ] at one year) was met for the full cohort, with a win ratio of 1.84. For the device and control groups, freedom from all-cause mortality and tricuspid valve surgery through 12 months was 90.6 and 89.9 percent, respectively. The annualized HFH rate was comparable between the groups (0.17 versus 0.20 events/patient-year for device versus control individuals). Overall, 49.5 percent of device individuals and 25.6 percent of control individuals achieved a ≥15-point KCCQ score improvement, indicating a significant treatment effect for quality of life. In addition, all secondary end points favored T-TEER.
"Changes in quality of life were associated with the degree of residual TR and the magnitude of TR reduction at one year," the authors write.
The study was funded by Abbott Vascular, the manufacturer of the TriClip device.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Low Rates of Isolated Locoregional Recurrence Seen in Young Women With Breast Cancer
TUESDAY, July 29, 2025 -- For women diagnosed with breast cancer at age 40 years or younger, the risk for isolated locoregional recurrence (LRR) is relatively low, according to a...
Perioperative Counseling Reduces Opioid Use After ACL Reconstruction Surgery
TUESDAY, July 29, 2025 -- Opioid-limiting pain management education and counseling reduce opioid consumption with no increase in postoperative pain among patients undergoing...
Risk-Reducing Mastectomy Cost-Effective With Breast Cancer Risk ≥35 Percent
MONDAY, July 28, 2025 -- Undergoing risk-reducing mastectomy (RRM) seems to be cost-effective for women aged 30 to 55 years with a lifetime breast cancer (BC) risk of 35 percent...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.